Sermorelin
Sermorelin — Growth Hormone Releasing Hormone (GHRH) analog, amino acids 1-29
A growth hormone releasing hormone fragment with a longer research and clinical history than many newer growth hormone secretagogues.
What Is Sermorelin?
Why Is Sermorelin Being Studied?
- Pituitary-stimulated natural growth hormone release
- Sleep quality and recovery
- Body composition and lean muscle research
- Age-related growth hormone decline
How Does It Work?
Sermorelin binds to GHRH receptors on the pituitary gland, stimulating it to produce and release growth hormone in a manner intended to preserve the body's natural pulsatile release pattern and feedback regulation (via somatostatin), rather than supplying growth hormone directly.
Sermorelin
Pituitary GHRH receptor activation
Natural, pulsatile growth hormone release
Downstream metabolic & recovery effects studied
What Does The Evidence Say?
Human Research
Sermorelin was studied in human clinical trials that supported a previously FDA-approved branded formulation for growth hormone deficiency evaluation and treatment, though that specific branded product has since been discontinued from the market.
Preclinical Research
Pharmacology studies characterized sermorelin's receptor binding and growth hormone-releasing activity in animal and laboratory models.
What We Don't Know Yet
Compounded sermorelin products available today have not individually undergone the same FDA review process as the original discontinued branded product. Long-term outcomes for wellness-focused (rather than deficiency-focused) use are less well studied.
Areas of Research
Longevity
Age-related growth hormone decline has made sermorelin a focus of healthy-aging research.
Sleep
Growth hormone release is linked to deep sleep stages, an area of research interest for GHRH analogs.
Muscle & Body Composition
Growth hormone pathway activity has been studied in relation to lean mass and metabolism.
Why Might Someone Discuss This With Their Provider?
Someone interested in a more physiologic approach to growth hormone pathway support may encounter sermorelin while comparing it to other secretagogues.
Whether a therapy is appropriate depends on individual health history, medications, goals and clinician evaluation.
Important Considerations
Sermorelin previously had an FDA-approved branded formulation (Geref) that has since been discontinued from the market. Compounded sermorelin available today is not itself an FDA-approved drug product.
Growth hormone pathway peptides can influence other hormone systems. Discuss candidacy, risks, and monitoring with a licensed healthcare provider before considering sermorelin.
Related Peptides
Tesamorelin
A growth hormone releasing hormone analog with a narrow FDA-approved indication for visceral fat reduction in a specific patient population.
Ipamorelin
A selective growth hormone secretagogue studied for its potential role in supporting the body's natural growth hormone pulses.
CJC-1295 / Ipamorelin
A two-peptide combination studied for its potential role in supporting the body's natural growth hormone release pathways.
Research & References
No references have been added for this entry yet. This library is updated on an ongoing basis.
The Peptide User Guide is provided for educational purposes and is not intended to diagnose, treat, cure, prevent, or provide individualized medical advice. Research surrounding many peptides and investigational therapies continues to evolve, and the strength of evidence varies significantly between compounds and applications. Treatment decisions should be made in consultation with a qualified healthcare professional.